C12Y 302/0105
Alpha-n-acetylglucosaminidase
Official title: Alpha-N-acetylglucosaminidase (3.2.1.50)
C12Y302/0105 (Alpha-n-acetylglucosaminidase) appears on 61 US grants and 93 published applications in this corpus.
Search patents in C12Y- Granted patents
- 61
- Published applications
- 93
- Assignees
- 45
- Inventors
- 169
- Latest grant
- 21 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 4 | 2 |
| 2003 | 0 | 1 |
| 2004 | 0 | 2 |
| 2005 | 0 | 1 |
| 2006 | 1 | 0 |
| 2007 | 1 | 2 |
| 2008 | 1 | 0 |
| 2009 | 1 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 7 |
| 2013 | 2 | 2 |
| 2014 | 1 | 5 |
| 2015 | 4 | 3 |
| 2016 | 4 | 7 |
| 2017 | 8 | 12 |
| 2018 | 1 | 5 |
| 2019 | 4 | 6 |
| 2020 | 7 | 6 |
| 2021 | 5 | 6 |
| 2022 | 4 | 5 |
| 2023 | 2 | 6 |
| 2024 | 4 | 7 |
| 2025 | 3 | 6 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- AAV-NAGLU vectors for treatment of mucopolysaccharidosis IIIB21 Apr 2026US 12,605,465 B2The University of North Carolina at Chapel Hill
- Vector compositions and methods of using same for treatment of lysosomal storage disorders9 Dec 2025US 12,492,412 B2M6P Terapeutics (Switzerland) LLC
- CNS delivery of therapeutic agents9 Sep 2025US 12,409,210 B2Takeda Pharmaceutical Company Limited
- Cleaning compositions containing Dispersins III6 May 2025US 12,291,696 B2Henkel AG & Co. KGaA
- Methods and compositions for CNS delivery of arylsulfatase A17 Dec 2024US 12,168,041 B2Takeda Pharmaceutical Company Limited
- Methods and pharmaceutical composition for the treatment of sanfilippo syndrome type iiib23 Jul 2026US 2026/0207719 A1Assistance Publique-HôPitaux De Paris (Aphp)
- Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof25 Dec 2025US 2025/0388644 A1Biomarin Pharmaceutical Inc.
- Cns delivery of therapeutic agents11 Dec 2025US 2025/0375506 A1Takeda Pharmaceutical Company Limited
- Methods for treating inherited metabolic disorders22 May 2025US 2025/0161354 A1BlueRock Therapeutics LP
- Methods and compositions for cns delivery of arylsulfatase a22 May 2025US 2025/0161417 A1Takeda Pharmaceutical Company Limited
Most cited
By later US patents
- Delivery of therapeutic compounds to the brain and other tissues90US 7,442,372 B2Biomarin Pharmaceutical Inc. · 2008
- Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases78US 9,249,424 B2HealthPartners Research & Education · 2016
- CNS delivery of therapeutic agents21US 9,283,181 B2Shire Human Genetic Therapies, Inc. · 2016
- Isolation and composition of novel glycosidases19US 6,300,113 B1New England Biolabs, Inc. · 2001
- Methods and compositions for CNS delivery of heparan N-sulfatase18US 9,320,711 B2Shire Human Genetic Therapies, Inc. · 2016